Eapm Working Group For Oncology Clinical Research

List of Publications by Year in Descending Order

51 papers	3,177 citations	24 h-index	56 g-index
62 ext. papers	4,190 ext. citations	7.3 avg, IF	5.33 L-index

#	Paper	IF	Citations
51	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.. *Npj Breast Cancer*, **2022**, 8, 1	7.8	0
50	Immunotherapy for early triple negative breast cancer: research agenda for the next decade.. *Npj Breast Cancer*, **2022**, 8, 23	7.8	7
49	Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial. *Cancer Research*, **2022**, 82, GS3-07-GS3-07	10.1	0
48	Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers.. *Frontiers in Medicine*, **2022**, 9, 863468	4.9	0
47	Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. *Nature Reviews Clinical Oncology*, **2021**,	19.4	56
46	Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?. *Breast*, **2021**, 55, 45-54	3.6	1
45	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. *Clinical Cancer Research*, **2021**, 27, 5096-5108	12.9	2
44	Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak. *Oncologist*, **2020**, 25, e1013-e1020	5.7	13
43	Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study **2020**,		58
42	Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial.. *Journal of Clinical Oncology*, **2020**, 38, 555-555	2.2	2
41	Is trastuzumab as a single agent obsolete in early breast cancer? No. *Breast*, **2019**, 43, 142-145	3.6	1
40	Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer. *Breast Cancer Research and Treatment*, **2018**, 167, 39-47	4.4	17
39	Demethylating agents to upregulate HLAs and antigen presenting machinery (APM) related genes in HER2+ breast cancer (BC) cell lines.. *Journal of Clinical Oncology*, **2018**, 36, e13012-e13012	2.2	
38	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. *Breast Cancer Research*, **2017**, 19, 16	8.3	52
37	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2 Breast Cancer. *Cancer Research*, **2017**, 77, 3280-3292	10.1	51
36	Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer. *Cancer Research* , **2017**, 77, 3317-3324	10.1	80
35	Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients. *Tumori*, **2017**, 103, 143-147	1.7	3

34	Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer. *JAMA Oncology*, **2017**, 3, 1707-1711	13.4	81
33	Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. *Breast Cancer Research and Treatment*, **2016**, 155, 223-34	4.4	3
32	New Strategies in Breast Cancer: Immunotherapy. *Clinical Cancer Research*, **2016**, 22, 2105-10	12.9	90
31	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 337-45	12.9	43
30	Residual disease after HER2-directed therapies in the neosphere study: Modulation of tumor lymphocyte infiltration (TIL) and prognosis.. *Journal of Clinical Oncology*, **2016**, 34, 517-517	2.2	1
29	Association between DNA level aberrations and immune cell infiltration in breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, 3078-3078	2.2	
28	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. *Cancer Science*, **2016**, 107, 1730-1735	6.9	75
27	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nature Reviews Clinical Oncology*, **2016**, 13, 674-690	19.4	1246
26	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. *Cancer Discovery*, **2015**, 5, 972-87	24.4	67
25	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. *Journal of the National Cancer Institute Monographs*, **2015**, 2015, 1-3	4.8	
24	Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. *Public Health Genomics*, **2015**, 18, 349-58	1.9	11
23	Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients. *PLoS ONE*, **2015**, 10, e0123194	3.7	9
22	Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.. *Journal of Clinical Oncology*, **2015**, 33, 11021-11021	2.2	
21	Low tumor-infiltrating lymphocytes (TILs) to predict and refine risk in patients not achieving a pathological complete response (pCR) in HER2-positive breast cancers.. *Journal of Clinical Oncology*, **2015**, 33, e11612-e11612	2.2	
20	The immune system and response to HER2-targeted treatment in breast cancer. *Lancet Oncology, The*, **2014**, 15, e58-68	21.7	171
19	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. *Clinical Cancer Research*, **2014**, 20, 511-21	12.9	143
18	OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. *Molecular Oncology*, **2014**, 8, 1196-207	7.9	17
17	TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. *Molecular Oncology*, **2014**, 8, 508-19	7.9	49

16	Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples. *PLoS ONE*, **2014**, 9, e86511	3.7	8
15	An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, 530-530	2.2	
14	DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. *Oncologist*, **2013**, 18, 1063-73	5.7	64
13	Breast cancer genomics: challenges in interpretation and application. *Oncologist*, **2013**, 18, e11-2	5.7	0
12	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. *Breast Cancer Research*, **2013**, 15, R86	8.3	33
11	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. *Journal of Clinical Oncology*, **2013**, 31, 1014-1014	2.2	2
10	Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. *Translational Oncology*, **2012**, 5, 155-9	4.9	13
9	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. *Breast Cancer Research and Treatment*, **2011**, 125, 785-95	4.4	54
8	First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. *Breast Cancer Research and Treatment*, **2011**, 130, 155-64	4.4	31
7	Surrogate markers for targeted therapy-based treatment activity and efficacy. *Journal of the National Cancer Institute Monographs*, **2011**, 2011, 91-4	4.8	2
6	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. *Journal of the National Cancer Institute*, **2011**, 103, 264-72	9.7	175
5	Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. *Clinical Cancer Research*, **2011**, 17, 2591-601	12.9	39
4	Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. *Cancer Research*, **2010**, 70, 8852-62	10.1	49
3	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. *Journal of Clinical Oncology*, **2010**, 28, 4316-23	2.2	163
2	Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. *Cancer Cell*, **2010**, 18, 423-35	24.3	116
1	Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. *Cancer*, **2010**, 116, 5161-7	6.4	76